Brief: Kiora's Investigational Treatment For Retinitis Pigmentosa, Kio-301, Demonstrates Visual Function Restoration In Patients Who Are Blind
27/04/2023 20:00
April 27 (Reuters) - Kiora Pharmaceuticals Inc:
* KIORA'S INVESTIGATIONAL TREATMENT FOR RETINITIS
PIGMENTOSA,
KIO-301, DEMONSTRATES VISUAL FUNCTION RESTORATION IN PATIENTS
WHO ARE BLIND
Further company coverage: KPRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kiora Pharmaceuticals
See all newsKiora Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kiora Pharmaceuticals, Inc. expected to post a loss of 62 cents a share - Earnings Preview
Brief: Kiora Pharmaceuticals Inc - Enters Securities Purchase Agreement On April 3, 2026 - SEC Filing
Kiora Pharmaceuticals posts 2025 net loss as expenses rise
Brief: Kiora Pharmaceuticals Files For Mixed Shelf Offering Of Up To $100 Million- SEC Filing